tirzepatide manufacturer FDA says shortage of GLP-1 is over Tirzep - ACI Pharmaceuticals

For people without pre-existing heart conditions, investing in these therapies still proves economically viable according to cardiovascular outcome trialsas shown by their favorable quality-adjusted life year (QALY) figureswhich underscores the broader value of GLP-1 agonists in improving cardiovascular outcomes

The same drug can cost $10 with one plan and $80 with another

GLP-1 weight-loss medications are changing how people approach food and drink

As of September 2023 it is on the FDA's Category 2 list of bulk drug substances that may not be compounded due to significant safety risks, and the agency has scheduled a Pharmacy Compounding Advisory Committee (PCAC) review for July 2026 covering proposed uses in opioid withdrawal, chronic insomnia, and narcolepsy

Injuries such as sciatic nerve damage, shoulder injury related to vaccine administration (SIRVA), and localized tissue necrosis are often preventableyet they continue to occur due to poor technique, inadequate training, or improper site selection

Obesity (Silver Spring) 2022;30:16081620